PMID: 6110913Mar 28, 1981Paper

Immunological and pharmacological monitoring in the clinical use of cyclosporin A

Lancet
P KeownW Howson

Abstract

Immunological reactivity to donor antigens and serum concentrations of cyclosporin A were monitored in six patients after renal transplantation. At concentrations of 0.1--1.0 microgram/ml cyclosporin A prevented both donor-specific immune reactivity and clinical rejection during the early post-transplant course. Measurement of cyclosporin A levels and immunological indices allowed individual adjustment of the dosage so as to give excellent early graft function with few adverse effects.

Citations

Oct 1, 1995·Journal of Clinical Pharmacology·C H d'UscioL Z Benet
Jan 1, 1991·European Journal of Clinical Pharmacology·A Lindholm
Oct 1, 1992·Digestive Diseases and Sciences·J F CadranelP Opolon
Jun 25, 1982·Pharmaceutisch Weekblad. Scientific Edition·E AbischM Trapp
Oct 1, 1984·Agents and Actions·A W ThomsonJ G Simpson
Jun 12, 2013·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Amudha PalanisamyBarry I Freedman
Jan 1, 1989·Pharmacology & Therapeutics·M A McMillan
Feb 1, 1986·Veterinary Immunology and Immunopathology·K S LatimerI M Kircher
Jan 1, 1986·International Journal of Immunopharmacology·O H NielsenJ Elmgreen
Mar 26, 2004·Transplantation Proceedings·B D Kahan
Dec 26, 2001·Transplantation Proceedings·B D Kahan
Jul 18, 1981·Lancet·E GluckmanA Baumelou
Oct 17, 1981·Lancet·B M HallJ Boulas
Sep 19, 1981·Lancet·M J Roddis
Jul 23, 1983·Lancet·E von Willebrand, P Häyry
Jan 1, 1983·Lancet·A LaupacisP Thibert
Jul 23, 1981·The New England Journal of Medicine·P A KeownR A Ulan
Jan 1, 1986·Therapeutic Drug Monitoring·R VenkataramananT E Starzl
Apr 1, 1987·Journal of Veterinary Internal Medicine·C R GregoryJ D Patz
Nov 1, 1986·The British Journal of Ophthalmology·T A Bell, A G Hunnisett
May 12, 1984·British Medical Journal·S RobsonR Williams
Jan 1, 1982·Immunological Reviews·S Britton, R Palacios
Dec 1, 1986·The British Journal of Surgery·S D ParvinP R Bell
Aug 1, 1988·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·L ReismanL Burrows
Mar 21, 1981·British Medical Journal·R Y CalneR Williams
Sep 11, 1982·British Medical Journal·A O LanglandsG M Kerr
Oct 1, 1982·The Journal of Pathology·J T BlairJ G Simpson
Jan 25, 2005·Therapeutic Drug Monitoring·Matthias Büchler, Atholl Johnston
Jan 1, 1996·Journal of Basic Microbiology·K Balakrishnan, A Pandey

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.